Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.55 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.55 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.55 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.55 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.50 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.50 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.49 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.48 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.48 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.48 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.58 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.55 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.53 |
| ▸ | DRD5 | P21918 | 1/20 | 0.49 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532484 | 0.98 | CD274 (0.59) | CD274HTR2CHTR2AHTR2BKCNH2 | |
| SCHEMBL8467911 | 0.98 | CD274 (0.59) | CD274HTR2CHTR2AHTR2BKCNH2 | |
| Hydrochloric Acid SCHEMBL1124555 | 0.93 | HTR2C (0.55) | CD274HTR2CHTR2AHTR2BKCNH2 | |
| Hydrochloric Acid SCHEMBL31062521 | 0.93 | HTR2C (0.55) | CD274HTR2CHTR2AHTR2BKCNH2 | |
| SCHEMBL746109 | 0.91 | HTR2C (0.57) | CD274HTR2CHTR2AHTR2BKCNH2 | |
| SCHEMBL29558442 | 0.91 | HTR2C (0.57) | CD274HTR2CHTR2AHTR2BKCNH2 | |
| Hydrochloric Acid SCHEMBL17965624 | 0.90 | KCNH2 (0.53) | CD274HTR2CHTR2AHTR2BKCNH2 | |
| Hydrochloric Acid SCHEMBL3694891 | 0.89 | HTR2C (0.58) | HTR2CHTR2AHTR2BDRD2DRD3 | |
| Oxalic Acid SCHEMBL7199943 | 0.89 | CD274 (0.52) | CD274HTR2CHTR2AHTR2BKCNH2 | |
| SCHEMBL4859823 | 0.88 | KCNH2 (0.54) | CD274HTR2CHTR2AHTR2BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617811-B2 | HPK1 inhibitors and uses thereof | REGOR PHARMACEUTICALS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12612424-B2 | HPK1 inhibitors and uses thereof | REGOR PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | Lee Moffitt Cancer Center and Research Institute, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| US-12497411-B2 | Muscarinic acetylcholine receptor subtype 4 antagonists in the treatment of anemia | COLD SPRING HARBOR LABORATORY (US) | 2025-12-16 | — | — | US | disclosed |
| EP-3463362-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| CN-114555585-B | HPK1 inhibitors and uses thereof | 锐格药业公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-116096370-B | HPK1 inhibitors and uses thereof | 锐格药业公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-113613650-B | Muscarinic acetylcholine receptor subtype 4 antagonists for treating anemia | 冷泉港实验室 | 2024-12-10 | — | — | CN | disclosed |
| WO-2024216197-A2 | COMPOUNDS AND METHODS FOR TREATING PROTEIN AGGREGATION DISEASES | ACELOT, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| US-20240174635-A1 | TLR 9 INHIBITORS | INSILICO MEDICINE IP LIMITED (HK) | 2024-05-30 | — | — | US | disclosed |
| EP-1511727-A2 | AROMATIC SULFONES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003099786-A2 | AROMATIC SULFONES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2003-12-04 | — | — | WO | disclosed |
| WO-1995007260-A1 | TETRAHYDROISOQUINOLINES AS ALPHA-2 ANTAGONISTS AND BIOGENIC AMINE UPTAKE INHIBITORS | ABBOTT LABORATORIES (US) | 1995-03-16 | — | — | WO | disclosed |
| US-5389638-A | Nervous system disorders | ABBOTT LABORATORIES (US) | 1995-02-14 | — | — | US | disclosed |
| EP-0266949-B1 | TETRAHYDROISOQUINOLIN-2-YL DERIVATIVES OF CARBOXYLIC ACIDS AS THROMBOXANE A2 ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-11-28 | — | — | EP | disclosed |
| US-4812573-A | ARYLSULFONAMIDE SUBSTITUTED TETRAHYDROISOQUINOLINYLALKANOIC ACIDS AS THROMBOXANE A2 ANTAGONISTS | SMITHKLINE & FRENCH LABORATORIES, LTD. (GB) | 1989-03-14 | — | — | US | disclosed |
| EP-0266949-A1 | Tetrahydroisoquinolin-2-yl derivatives of carboxylic acids as thromboxane A2 antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1988-05-11 | — | — | EP | disclosed |
| WO-1988003137-A1 | TETRAHYDROISOQUINOLIN-2-YL DERIVATIVES OF CARBOXYLIC ACIDS AS THROMBOXANE A2 ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1988-05-05 | — | — | WO | disclosed |
| US-4717724-A | FUNGICIDES, ANTIPROTOZOA, BACTERICIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-01-05 | — | — | US | disclosed |
| EP-0121753-A2 | 1-(1,3-Dioxolan-2-ylmethyl)-azoles, their salts, processes for their preparation and pharmaceutical compositions containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612424-B2 | HPK1 inhibitors and uses thereof | NEK11, NEK1, CSNK1A1 | HTR2C 2173/4885HTR2A 2117/4885HTR2B 2600/4885 |
| US-12617811-B2 | HPK1 inhibitors and uses thereof | MAP2K4, MAP2K1, MAP2K3 | HTR2C 2819/4885HTR2A 3887/4885HTR2B 3094/4885 |
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | CRBN, CD4, ICOS | HTR2C 1776/4885HTR2A 1639/4885HTR2B 2370/4885 |
| US-12497411-B2 | Muscarinic acetylcholine receptor subtype 4 antagonists in the treatment of anemia | CHRNE, CHRNG, CHRM4 | HTR2C 1171/4885HTR2A 861/4885HTR2B 789/4885 |
| US-20240174635-A1 | TLR 9 INHIBITORS | TLR9, TLR1, TLR7 | HTR2C 1461/4885HTR2A 767/4885HTR2B 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.